Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 18:12:3365-3379.
doi: 10.2147/JPR.S231237. eCollection 2019.

Effect Of E-OA-07 On Improving Joint Health And Mobility In Individuals With Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Shalini Srivastava  1 , Jayesh A Chaudhary  2 , Robert N Girandola  3
Affiliations

Effect Of E-OA-07 On Improving Joint Health And Mobility In Individuals With Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Shalini Srivastava et al. J Pain Res. .

Abstract

Aim: The aim of the present study was to evaluate the effect of E-OA-07 on individuals having osteoarthritis of the knee.

Background: Lanconone® (E-OA-07) is a widely marketed dietary supplement which has been previously studied in different clinical settings for managing chronic joint pain. This was a confirmatory study planned at a lowered dose regimen with the purpose of improving compliance and reducing consumer cost.

Methods: Male and female participants aged between 40 and 65 years, with history of joint pain for at least 3 years, were recruited. Knee joint dysfunction of grade II/III was radiographically characterized as per Kellgren-Lawrence system of classification. Enrolled participants were randomized to receive E-OA-07 at a dose of 1000 mg/day or placebo over a period of 8 weeks. The primary efficacy parameter was assessment of change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. Whereas, the secondary parameters explored in the study included WOMAC subscales of stiffness and physical function, EQ-5D-5L questionnaire, systemic inflammatory marker (hs-CRP) and self-assessment of treatment satisfaction.

Results: At the end of 8 weeks, joint pain severity as per WOMAC was found to be significantly reduced in the E-OA-07 group as compared to placebo (p<0.001). Similar improvement was observed in the subscales of stiffness and physical function which corresponds to significant improvement in the quality-of-life standards of E-OA-07 participants (p<0.001), reporting higher treatment satisfaction (p<0.001).

Conclusion: E-OA-07 at a dose of 1000 mg/day was able to significantly reduce joint pain and thereby improve joint mobility in study participants. At the end of the study period, there was a clinically relevant change of 45.55%, 45.91% and 38.19% for pain, stiffness and physical function, respectively. Moving forward, studies could be planned for understanding the cartilage regenerative properties of E-OA-07.

Keywords: Boswellia serrata; WOMAC; dietary supplement; joint inflammation; joint pain; osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

Dr. Shalini Srivastava and Mr. Jayesh A Chaudhary are affiliated to Enovate Biolife and Vedic Lifesciences. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Participants Flow In The Study.
Figure 2
Figure 2
Changes in WOMAC subscale mean score (A) pain, (B) stiffness, (C) physical function, and (D) total WOMAC. Data are represented as Mean ± SD. *p<0.05 and **p<0.001.
Figure 3
Figure 3
Quality-of-life score response to placebo and E-OA-07 therapy. Significant improvement was observed in each of the domains: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. *p <0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mobasheri A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr Rheumatol Rep. 2013;15(10):364. doi:10.1007/s11926-013-0364-9 - DOI - PMC - PubMed
    1. Zhang W, Ouyang H, Dass CR, Xu J. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016;4:15040. doi:10.1038/boneres.2015.40 - DOI - PMC - PubMed
    1. U. S. Food and Drug Administration. Center for Drug Evaluation and Research. FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes: FDA Drug Safety Communication; 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-c.... - PubMed
    1. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-Week, double-blind, multiple-dose, placebo-controlled trial. Arch Intern Med. 2000;160(19):2947–2954. doi:10.1001/archinte.160.19.2947 - DOI - PubMed
    1. Hawker GA, White D, Skou ST. Non-pharmacological management of osteoarthritis. Osteoarthritis Cartilage. 2017;25(1):S4. doi:10.1016/j.joca.2017.02.013 - DOI